Lv1
22 积分 2024-06-13 加入
Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system
2天前
已完结
Zanubrutinib, Lenalidomide, and Rituximab Demonstrate Efficacy in Relapsed/Refractory Central Nervous System Lymphoma: A Single - Center Retrospective Study
2天前
已完结
The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma
22天前
已完结
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
22天前
已完结
Triplet Therapies in Chronic Lymphocytic Leukemia
22天前
已完结
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
22天前
已完结
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study
1个月前
已完结
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
1个月前
已完结
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial
1个月前
已完结
Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era
1个月前
已完结
皖公网安备34019202002308
